SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner

BACKGROUND: Cisplatin (DDP) remains the backbone of chemotherapy for non-small cell lung cancer (NSCLC), yet its clinical efficacy is limited by DDP resistance. We aim to investigate the role of the SET and MYND domain-containing protein 3 (SMYD3) in DDP resistance of NSCLC. METHODS: Expression patt...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Hong-Wei, Xing, Wen-Qun, Ba, Yu-Feng, Li, Hao-Miao, Wang, Hao-Ran, Li, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027902/
https://www.ncbi.nlm.nih.gov/pubmed/33773404
http://dx.doi.org/10.1016/j.tranon.2021.101075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027902/
https://www.ncbi.nlm.nih.gov/pubmed/33773404
http://dx.doi.org/10.1016/j.tranon.2021.101075

Ejemplares similares